Aslı Vural1, Dilbade Yıldız Ekinci2, Ismail Umut Onur3, Gülsüm Oya Hergünsel4, Fadime Ulviye Yiğit3. 1. Ophthalmology Clinics, Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Bakirkoy, Istanbul, Turkey. asli.deger@hotmail.com. 2. Ophthalmology Clinics, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey. 3. Ophthalmology Clinics, Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Bakirkoy, Istanbul, Turkey. 4. Anesthesiology Clinics, Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Abstract
PURPOSE: To investigate the extent of vascularization of the peripheral retina and vascular development patterns in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of bevacizumab (IVB) and compare fluorescein angiography (FA) findings of them to those seen in patients with type 2 ROP who have recovered spontaneously. METHODS: Between May 2014 and September 2016, patients with type 1 ROP who had a single 0.025 ml (0.625 mg) IVB were evaluated as study group. On the other hand, type 2 ROP patients with stage 2 or stage 3 ROP in zone II without plus disease on indirect ophthalmoscopy were not treated and included as a control group. The progression of ROP and vascularization of retina were evaluated by FA under sedation analgesia in all patients. RESULTS: Sixty-two eyes of 31 premature infants were included in the study: 36 eyes/18 patients were treated for type 1 ROP and 26 eyes/13 patients were followed conservatively with the diagnoses of type 2 ROP. In the last FA examination among the study group, vascular terminal was in zone II in 8 eyes/4 patients (22.22%) and in zone III in 28 eyes/14 patients (77.78%). Vascular terminal was in zone III in all eyes of the control group (100%). We noted circumferential vessels in 12 eyes/8 patients (33.3%) and 7 eyes/5 patients (26.92%) in the study and control groups, respectively. Abnormal branching was noticed in 13 eyes/7 patients (46.42%) in the control group, whereas it was not detected in the study group. Arteriovenous shunts were noted in 1 eye of a patient in the study group and in 5 eyes/4 patients in the control group. In 6 eyes/3 patients among the study group, we performed laser photocoagulation to the avascular retina because of profound vascular leakage. CONCLUSION: Peripheral vascular abnormalities probably occur as a result of ROP itself because similar FA findings were detected both in type 1 and type 2 ROP patients with or without treatment, although significantly less in IVB-treated group. Retinal vascularization usually reaches the farthermost limits with time even though it slows down in eyes treated with IVB, indicating the importance of a longer follow-up.
PURPOSE: To investigate the extent of vascularization of the peripheral retina and vascular development patterns in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of bevacizumab (IVB) and compare fluorescein angiography (FA) findings of them to those seen in patients with type 2 ROP who have recovered spontaneously. METHODS: Between May 2014 and September 2016, patients with type 1 ROP who had a single 0.025 ml (0.625 mg) IVB were evaluated as study group. On the other hand, type 2 ROP patients with stage 2 or stage 3 ROP in zone II without plus disease on indirect ophthalmoscopy were not treated and included as a control group. The progression of ROP and vascularization of retina were evaluated by FA under sedation analgesia in all patients. RESULTS: Sixty-two eyes of 31 premature infants were included in the study: 36 eyes/18 patients were treated for type 1 ROP and 26 eyes/13 patients were followed conservatively with the diagnoses of type 2 ROP. In the last FA examination among the study group, vascular terminal was in zone II in 8 eyes/4 patients (22.22%) and in zone III in 28 eyes/14 patients (77.78%). Vascular terminal was in zone III in all eyes of the control group (100%). We noted circumferential vessels in 12 eyes/8 patients (33.3%) and 7 eyes/5 patients (26.92%) in the study and control groups, respectively. Abnormal branching was noticed in 13 eyes/7 patients (46.42%) in the control group, whereas it was not detected in the study group. Arteriovenous shunts were noted in 1 eye of a patient in the study group and in 5 eyes/4 patients in the control group. In 6 eyes/3 patients among the study group, we performed laser photocoagulation to the avascular retina because of profound vascular leakage. CONCLUSION: Peripheral vascular abnormalities probably occur as a result of ROP itself because similar FA findings were detected both in type 1 and type 2 ROP patients with or without treatment, although significantly less in IVB-treated group. Retinal vascularization usually reaches the farthermost limits with time even though it slows down in eyes treated with IVB, indicating the importance of a longer follow-up.
Entities:
Keywords:
Bevacizumab; Fluorescein angiography; Peripheral vascular abnormalities; Retinopathy of prematurity
Authors: Jose M Garcia Gonzalez; Laura Snyder; Michael Blair; Ashley Rohr; Michael Shapiro; Mark Greenwald Journal: Retina Date: 2018-04 Impact factor: 4.256
Authors: María A Martínez-Castellanos; Shulamit Schwartz; Myriam L Hernández-Rojas; Veronica A Kon-Jara; Gerardo García-Aguirre; José L Guerrero-Naranjo; R V Paul Chan; Hugo Quiroz-Mercado Journal: Retina Date: 2013-02 Impact factor: 4.256
Authors: Björn C Harder; Frank C Schlichtenbrede; Stefan von Baltz; Waldemar Jendritza; Bettina Jendritza; Jost B Jonas Journal: Am J Ophthalmol Date: 2013-03-12 Impact factor: 5.258
Authors: Haibo Wang; Zhihong Yang; Yanchao Jiang; John Flannery; Scott Hammond; Tal Kafri; Sai Karthik Vemuri; Bryan Jones; M Elizabeth Hartnett Journal: Invest Ophthalmol Vis Sci Date: 2014-02-04 Impact factor: 4.799
Authors: Megan M Geloneck; Alice Z Chuang; W Lloyd Clark; Michael G Hunt; Alan A Norman; Eric A Packwood; Khaled A Tawansy; Helen A Mintz-Hittner Journal: JAMA Ophthalmol Date: 2014-11 Impact factor: 7.389
Authors: Martin Hložánek; Zbyněk Straňák; Zuzana Terešková; Jan Mareš; Inka Krejčířová; Marie Česká Burdová Journal: Diagnostics (Basel) Date: 2022-05-18